{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:33:35Z","timestamp":1790253215219,"version":"4.1.0"},"reference-count":170,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"the National Research Foundation of Korea (NRF)","doi-asserted-by":"publisher","award":["2018R1D1A1B07045762"],"award-info":[{"award-number":["2018R1D1A1B07045762"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Atopic dermatitis (AD) is a chronically relapsing inflammatory skin disorder characterized by itching and eczematous lesions. It is often associated with a personal or familial history of allergic diseases. Allergic inflammation induced by immunoglobulin E and T-helper type 2 (Th2) cell responses to common environmental agents has been suggested to play an essential role in AD pathogenesis. The standard therapies for AD, including topical or systemic agents, focus on controlling skin inflammation. Recently developed monoclonal antibody to interleukin-4 receptor alpha or Janus kinase inhibitors can provide significant clinical improvements in patients with AD by inhibiting Th2 cell-mediated skin inflammation. However, the clinical efficacy of the Th2 cell-targeted therapy is transient and incomplete in patients with AD. Patients with AD are seeking a permanent cure. Therefore, the development of novel immunomodulatory strategies that can improve a long-term clinical outcome and provide a long-term treatment-free clinical remission of AD (disease-modifying therapy) is needed. Regulatory T (Treg) cells play a critical role in the maintenance of immune tolerance and suppress the development of autoimmune and allergic diseases. This review provides three working hypotheses and perspectives for the treatment of AD by Treg cell activation. (1) A decreased number or function of Treg cells is a critical event that causes the activation of Th2 cells, leading to the development and maintenance of AD. (2) Activation of Treg cells is an effective therapeutic approach for AD. (3) Many different immunomodulatory strategies activating Treg cells can provide a long-term clinical improvement of AD by induction of immune tolerance. The Treg cell-targeted immunomodulatory therapies for AD include allergen immunotherapy, microbiota, vitamin D, polyvalent human immunoglobulin G, monoclonal antibodies to the surface antigens of T cell or antigen-presenting cell, and adoptive transfer of autologous Treg cells or genetically engineered Treg cells expanded in vitro.<\/jats:p>","DOI":"10.3390\/life13081674","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T09:14:40Z","timestamp":1690881280000},"page":"1674","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Regulatory T Cell-Targeted Immunomodulatory Therapy for Long-Term Clinical Improvement of Atopic Dermatitis: Hypotheses and Perspectives"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5253-6577","authenticated-orcid":false,"given":"Dong-Ho","family":"Nahm","sequence":"first","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon 16499, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1111\/jdv.16892","article-title":"ETFAD\/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children","volume":"34","author":"Wollenberg","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jaip.2020.11.034","article-title":"Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect","volume":"9","author":"Ratchataswan","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.5021\/ad.2015.27.4.355","article-title":"Personalized Immunomodulatory Therapy for Atopic Dermatitis: An Allergist\u2019s View","volume":"27","author":"Nahm","year":"2015","journal-title":"Ann. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jdermsci.2018.01.016","article-title":"Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis","volume":"90","author":"Wang","year":"2018","journal-title":"J. Dermatol. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1159\/000518541","article-title":"Efficacy and Safety of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis","volume":"238","author":"Li","year":"2022","journal-title":"Dermatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): Results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Teixeira","year":"2021","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jaci.2005.10.040","article-title":"Absence of T-regulatory cell expression and function in atopic dermatitis skin","volume":"117","author":"Verhagen","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1038\/jid.2012.40","article-title":"Foxp3+ cells control Th2 responses in a murine model of atopic dermatitis","volume":"132","author":"Fyhrquist","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s40257-016-0209-1","article-title":"Complementary and Alternative Medicine for Atopic Dermatitis: An Evidence-Based Review","volume":"17","author":"Vieira","year":"2016","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6047","DOI":"10.1016\/j.scitotenv.2010.08.047","article-title":"Sensitivity-related illness: The escalating pandemic of allergy, food intolerance and chemical sensitivity","volume":"408","author":"Genuis","year":"2010","journal-title":"Sci. Total Env."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4168\/aair.2014.6.6.517","article-title":"Relationship between indoor air pollutant levels and residential environment in children with atopic dermatitis","volume":"6","author":"Lee","year":"2014","journal-title":"Allergy Asthma Immunol. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jaci.2014.09.023","article-title":"The role of air pollutants in atopic dermatitis","volume":"134","author":"Ahn","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12940-017-0225-5","article-title":"Exposure to phthalates and bisphenol A are associated with atopic dermatitis symptoms in children: A time-series analysis","volume":"16","author":"Kim","year":"2017","journal-title":"Environ. Health"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1111\/j.1398-9995.2006.01209.x","article-title":"Effect of climatic change in children with atopic eczema","volume":"61","author":"Byremo","year":"2006","journal-title":"Allergy"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/j.1365-2133.2008.08518.x","article-title":"Heliotherapy improves vitamin D balance and atopic dermatitis","volume":"158","author":"Vahavihu","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3349\/ymj.2016.57.2.393","article-title":"Retrospective Analysis on the Effects of House Dust Mite Specific Immunotherapy for More Than 3 Years in Atopic Dermatitis","volume":"57","author":"Lee","year":"2016","journal-title":"Yonsei Med. J."},{"key":"ref_18","first-page":"609","article-title":"Remission of life-long atopic dermatitis after hyposensitisation to house dust mite","volume":"229","author":"Chait","year":"1985","journal-title":"Practitioner"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000247754","article-title":"Injection of allergen-antibody complexes is an effective treatment of atopic dermatitis","volume":"182","author":"Leroy","year":"1991","journal-title":"Dermatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0021-8707(60)90019-8","article-title":"Studies in atopic dermatitis. V. Problems in inhalant hyposensitization and results of treatment","volume":"31","author":"Tuft","year":"1960","journal-title":"J. Allergy"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/bjd.12603","article-title":"The natural course of early-onset atopic dermatitis in Taiwan: A population-based cohort study","volume":"170","author":"Hua","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1365-2796.2007.01855.x","article-title":"Immune tolerance: Mechanisms and application in clinical transplantation","volume":"262","author":"Sykes","year":"2007","journal-title":"J. Intern. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"102242","DOI":"10.1016\/j.coph.2022.102242","article-title":"Immune tolerance therapies for autoimmune diseases: Shifting the goalpost to cure","volume":"65","author":"Sharkey","year":"2022","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nrd2653","article-title":"Therapeutic manipulation of immune tolerance in allergic disease","volume":"8","author":"Akdis","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1073\/pnas.93.5.2019","article-title":"Pathogenic autoantibodies are routinely generated during the response to foreign antigen: A paradigm for autoimmune disease","volume":"93","author":"Ray","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/cbin.11517","article-title":"Dysregulation of the immune response in coronavirus disease 2019","volume":"45","author":"Rezaei","year":"2021","journal-title":"Cell Biol. Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nm0804-801","article-title":"Regulatory T cells and mechanisms of immune system control","volume":"10","author":"Vieira","year":"2004","journal-title":"Nat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.molmed.2007.01.003","article-title":"Natural regulatory T cells: Mechanisms of suppression","volume":"13","author":"Miyara","year":"2007","journal-title":"Trends Mol. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jaci.2009.03.001","article-title":"Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion","volume":"123","author":"Miyara","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fimmu.2013.00152","article-title":"Generation and function of induced regulatory T cells","volume":"4","author":"Schmitt","year":"2013","journal-title":"Front. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","article-title":"Regulatory T Cells and Human Disease","volume":"38","author":"Sakaguchi","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41573-019-0041-4","article-title":"Next-generation regulatory T cell therapy","volume":"18","author":"Ferreira","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ni904","article-title":"Foxp3 programs the development and function of CD4+CD25+ regulatory T cells","volume":"4","author":"Fontenot","year":"2003","journal-title":"Nat. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jaut.2017.03.007","article-title":"Central immune tolerance depends on crosstalk between the classical and alternative NF-\u03baB pathways in medullary thymic epithelial cells","volume":"81","author":"Riemann","year":"2017","journal-title":"J. Autoimmun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"a006957","DOI":"10.1101\/cshperspect.a006957","article-title":"T-cell tolerance: Central and peripheral","volume":"4","author":"Xing","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1172\/JCI118963","article-title":"Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro","volume":"98","author":"Akdis","year":"1996","journal-title":"J. Clin. Investig."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1172\/JCI2250","article-title":"Role of interleukin 10 in specific immunotherapy","volume":"102","author":"Akdis","year":"1998","journal-title":"J. Clin. Investig."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1067\/mai.2003.1570","article-title":"Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy","volume":"111","author":"Francis","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/eji.200322919","article-title":"IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy","volume":"33","author":"Jutel","year":"2003","journal-title":"Eur. J. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.coi.2006.06.003","article-title":"Healthy immune response to allergens: T regulatory cells and more","volume":"18","author":"Akdis","year":"2006","journal-title":"Curr. Opin. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1084\/jem.20032058","article-title":"Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells","volume":"199","author":"Akdis","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jaci.2021.08.008","article-title":"Inborn errors of immunity manifesting as atopic disorders","volume":"148","author":"Smith","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s10875-022-01289-3","article-title":"Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee","volume":"42","author":"Tangye","year":"2022","journal-title":"J. Clin. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2133.2008.08835.x","article-title":"Cutaneous manifestations of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome","volume":"160","author":"Ruemmele","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"49.25","DOI":"10.4049\/jimmunol.184.Supp.49.25","article-title":"Defects of Regulatory T Cell function In The Wiskott-Aldrich Syndrome. (49.25)","volume":"184","author":"Adriani","year":"2010","journal-title":"J. Immunol."},{"key":"ref_47","first-page":"125","article-title":"Eczema in primary immune-deficiencies. Clues to the pathogenesis of atopic dermatitis with special reference to the Wiskott-Aldrich syndrome","volume":"114","author":"Saurat","year":"1985","journal-title":"Acta Derm. -Venereol. Suppl."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S0091-6749(98)70271-4","article-title":"Allergen immunotherapy: Therapeutic vaccines for allergic diseases. A WHO position paper","volume":"102","author":"Bousquet","year":"1998","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2013.02.044","article-title":"Efficacy of allergen-specific immunotherapy for atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials","volume":"132","author":"Bae","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jaci.2022.09.020","article-title":"Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms","volume":"151","author":"Guyatt","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40413-015-0063-2","article-title":"Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens","volume":"8","author":"Akdis","year":"2015","journal-title":"World Allergy Organ. J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.alit.2020.08.002","article-title":"Mechanisms of allergen-specific immunotherapy and allergen tolerance","volume":"69","author":"Kucuksezer","year":"2020","journal-title":"Allergol. Int."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.immuni.2018.12.001","article-title":"The Biology of T Regulatory Type 1 Cells and Their Therapeutic Application in Immune-Mediated Diseases","volume":"49","author":"Roncarolo","year":"2018","journal-title":"Immunity"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jaci.2022.06.024","article-title":"Single-cell immunoprofiling after immunotherapy for allergic rhinitis reveals functional suppression of pathogenic T(H)2 cells and clonal conversion","volume":"150","author":"Iinuma","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2174\/1381612033392224","article-title":"Probiotics as biotherapeutic agents: Present knowledge and future prospects","volume":"9","author":"Mercenier","year":"2003","journal-title":"Curr. Pharm. Des."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3389\/fmicb.2016.00507","article-title":"Probiotics and Atopic Dermatitis: An Overview","volume":"7","author":"Rather","year":"2016","journal-title":"Front. Microbiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00004836-200308000-00004","article-title":"New scientific paradigms for probiotics and prebiotics","volume":"37","author":"Reid","year":"2003","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1046\/j.1365-2222.2000.00943.x","article-title":"Probiotics in the management of atopic eczema","volume":"30","author":"Isolauri","year":"2000","journal-title":"Clin. Exp. Allergy"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1142S","DOI":"10.1093\/ajcn\/73.6.1142S","article-title":"Probiotics in human disease","volume":"73","author":"Isolauri","year":"2001","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jaci.2015.04.031","article-title":"Probiotics for the prevention of allergy: A systematic review and meta-analysis of randomized controlled trials","volume":"136","author":"Brozek","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.clim.2014.04.008","article-title":"Effects of Lactobacillus rhamnosus on allergic march model by suppressing Th2, Th17, and TSLP responses via CD4+CD25+Foxp3+ Tregs","volume":"153","author":"Kim","year":"2014","journal-title":"Clin. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jaci.2011.02.025","article-title":"Bacterial components plus vitamin D: The ultimate solution to the asthma (autoimmune disease) epidemic?","volume":"127","author":"Weiss","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/pai.13305","article-title":"Comparative effectiveness of probiotic strains for the treatment of pediatric atopic dermatitis: A systematic review and network meta-analysis","volume":"32","author":"Mantaring","year":"2021","journal-title":"Pediatr. Allergy Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1080\/09546634.2022.2080170","article-title":"The efficacy of probiotics supplementation for the treatment of atopic dermatitis in adults: A systematic review and meta-analysis","volume":"33","author":"Li","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/pai.13514","article-title":"Comparative effectiveness of probiotic strains on the prevention of pediatric atopic dermatitis: A systematic review and network meta-analysis","volume":"32","author":"Recto","year":"2021","journal-title":"Pediatr. Allergy Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/j.1365-2222.2009.03305.x","article-title":"Probiotics for the treatment of eczema: A systematic review","volume":"39","author":"Boyle","year":"2009","journal-title":"Clin. Exp. Allergy"},{"key":"ref_67","first-page":"CD006135","article-title":"Probiotics for treating eczema","volume":"11","author":"Makrgeorgou","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1079\/NRR200479","article-title":"Dietary modulation of the human colonic microbiota: Updating the concept of prebiotics","volume":"17","author":"Gibson","year":"2004","journal-title":"Nutr. Res. Rev."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/imcb.12409","article-title":"Impact of prebiotics on immune response: From the bench to the clinic","volume":"99","author":"Pujari","year":"2021","journal-title":"Immunol. Cell Biol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/j.1365-2222.2009.03295.x","article-title":"Clinical effects of kestose, a prebiotic oligosaccharide, on the treatment of atopic dermatitis in infants","volume":"39","author":"Shibata","year":"2009","journal-title":"Clin. Exp. Allergy"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"271","DOI":"10.4168\/aair.2023.15.3.271","article-title":"The Effect of Prebiotics on Atopic Dermatitis","volume":"15","author":"Ahn","year":"2023","journal-title":"Allergy Asthma Immunol. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1038\/s41467-018-07359-8","article-title":"Therapeutic faecal microbiota transplantation controls intestinal inflammation through IL10 secretion by immune cells","volume":"9","author":"Burrello","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s12276-021-00627-6","article-title":"Gut microbiota restoration through fecal microbiota transplantation: A new atopic dermatitis therapy","volume":"53","author":"Kim","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e570","DOI":"10.1002\/iid3.570","article-title":"Clinical efficacy of fecal microbial transplantation treatment in adults with moderate-to-severe atopic dermatitis","volume":"10","author":"Mashiah","year":"2022","journal-title":"Immun. Inflamm. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Fisher, S.A., Rahimzadeh, M., Brierley, C., Gration, B., Doree, C., Kimber, C.E., Plaza Cajide, A., Lamikanra, A.A., and Roberts, D.J. (2019). The role of vitamin D in increasing circulating T regulatory cell numbers and modulating T regulatory cell phenotypes in patients with inflammatory disease or in healthy volunteers: A systematic review. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0222313"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2133.2008.08601.x","article-title":"Randomized controlled trial of vitamin D supplementation for winter-related atopic dermatitis in Boston: A pilot study","volume":"159","author":"Sidbury","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4168\/aair.2013.5.4.207","article-title":"Correlation between serum vitamin D level and the severity of atopic dermatitis associated with food sensitization","volume":"5","author":"Lee","year":"2013","journal-title":"Allergy Asthma Immunol. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1002\/eji.200839103","article-title":"Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: Differential role for PD-L1","volume":"39","author":"Unger","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1084\/jem.20011629","article-title":"In vitro generation of interleukin 10\u2013producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)\u2013and Th2-inducing cytokines","volume":"195","author":"Barrat","year":"2002","journal-title":"J. Exp. Med."},{"key":"ref_80","first-page":"387","article-title":"Ligation of TLR9 induced on human IL-10-secreting Tregs by 1alpha,25-dihydroxyvitamin D3 abrogates regulatory function","volume":"119","author":"Urry","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jsbmb.2010.02.029","article-title":"Regulatory T cells, inflammation and the allergic response-The role of glucocorticoids and Vitamin D","volume":"120","author":"Dimeloe","year":"2010","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1426503","DOI":"10.1155\/2016\/1426503","article-title":"Dietary Vitamin D Increases Percentages and Function of Regulatory T Cells in the Skin-Draining Lymph Nodes and Suppresses Dermal Inflammation","volume":"2016","author":"Gorman","year":"2016","journal-title":"J. Immunol. Res."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Li, Q., Zhou, Q., Zhang, G., Tian, X., Li, Y., Wang, Z., Zhao, Y., Chen, Y., and Luo, Z. (2022). Vitamin D Supplementation and Allergic Diseases during Childhood: A Systematic Review and Meta-Analysis. Nutrients, 14.","DOI":"10.3390\/nu14193947"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1056\/NEJM199107113250207","article-title":"The use of intravenous immune globulin in immunodeficiency diseases","volume":"325","author":"Buckley","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMra1009433","article-title":"Intravenous immune globulin in autoimmune and inflammatory diseases","volume":"367","author":"Gelfand","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.4049\/jimmunol.179.8.5571","article-title":"Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function","volume":"179","author":"Kessel","year":"2007","journal-title":"J. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e28075","DOI":"10.1002\/pbc.28075","article-title":"Intravenous immunoglobulin therapy enhances suppressive regulatory T cells and decreases innate lymphoid cells in children with immune thrombocytopenia","volume":"67","author":"Wang","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3899\/jrheum.110981","article-title":"High-dose intravenous immunoglobulin treatment increases regulatory T cells in patients with eosinophilic granulomatosis with polyangiitis","volume":"39","author":"Tsurikisawa","year":"2012","journal-title":"J. Rheumatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.it.2017.08.008","article-title":"Circulating normal IgG as stimulator of regulatory T cells: Lessons from intravenous immunoglobulin","volume":"38","author":"Maddur","year":"2017","journal-title":"Trends Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/blood-2007-03-079947","article-title":"Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: A critical factor in controlling experimental autoimmune encephalomyelitis","volume":"111","author":"Ephrem","year":"2008","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: A review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_93","unstructured":"Clinical Research Group for Histaglobin (1980). Double blind controlled study on the efficacy of histaglobin on chronic urticaria and eczematous dermatitis (in Japanese). Nishinipponifuka, 42, 470\u2013477."},{"key":"ref_94","first-page":"537","article-title":"Value of Allerglobulin in the treatment of atopic dermatitis in children and young adults. A double-blind randomized study","volume":"7","year":"1986","journal-title":"Rev. Med. Interne"},{"key":"ref_95","first-page":"373","article-title":"Towards a network theory of the immune system","volume":"125C","author":"Jerne","year":"1974","journal-title":"Ann. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1016\/j.molimm.2007.01.005","article-title":"Immunogenicity of autologous immunoglobulins: Principles and practices","volume":"44","author":"Vazquez","year":"2007","journal-title":"Mol. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nm0104-17","article-title":"The idiotypic network in autoimmunity: Antibodies that bind antibodies that bind antibodies","volume":"10","author":"Shoenfeld","year":"2004","journal-title":"Nat. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fimmu.2014.00086","article-title":"Self-tolerance in a minimal model of the idiotypic network","volume":"5","author":"Schulz","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/WOX.0b013e3181e61ebf","article-title":"Anti-ids in allergy: Timeliness of a classic concept","volume":"3","author":"Wallmann","year":"2010","journal-title":"World Allergy Organ. J."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4168\/aair.2014.6.1.89","article-title":"Autologous immunoglobulin therapy in patients with severe recalcitrant atopic dermatitis: A preliminary report","volume":"6","author":"Nahm","year":"2014","journal-title":"Allergy Asthma Immunol. Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000431173","article-title":"Effects of Intramuscular Injection of Autologous Immunoglobulin on Clinical Severity and Serum IgE Concentration in Patients with Atopic Dermatitis","volume":"231","author":"Nahm","year":"2015","journal-title":"Dermatology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4168\/aair.2016.8.4.375","article-title":"Autologous Immunoglobulin Therapy in Patients With Severe Recalcitrant Atopic Dermatitis: Long-Term Changes of Clinical Severity and Laboratory Parameters","volume":"8","author":"Nahm","year":"2016","journal-title":"Allergy Asthma Immunol. Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.intimp.2017.08.020","article-title":"Immunomodulatory effects induced by intramuscular administration of autologous total immunoglobulin G in patients with atopic dermatitis","volume":"52","author":"Cho","year":"2017","journal-title":"Int. Immunopharmacol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"949","DOI":"10.4168\/aair.2020.12.6.949","article-title":"Efficacy, Safety, and Immunomodulatory Effect of the Intramuscular Administration of Autologous Total Immunoglobulin G for Atopic Dermatitis: A Randomized Clinical Trial","volume":"12","author":"Nahm","year":"2020","journal-title":"Allergy Asthma Immunol. Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e29486","DOI":"10.1097\/MD.0000000000029486","article-title":"Intramuscular administration of autologous total immunoglobulin G induces immunomodulatory effects on T cells in healthy human subjects: An open-labeled prospective single-arm trial","volume":"101","author":"Kwon","year":"2022","journal-title":"Medicine"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/ijd.13907","article-title":"IgG from atopic dermatitis patients induces IL-17 and IL-10 production in infant intrathymic TCD4 and TCD8 cells","volume":"57","author":"Sgnotto","year":"2018","journal-title":"Int. J. Dermatol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Fagundes, B.O., de Sousa, T.R., Nascimento, A., Fernandes, L.A., Sgnotto, F.D.R., Orfali, R.L., Aoki, V., Duarte, A., Sanabani, S.S., and Victor, J.R. (2022). IgG from Adult Atopic Dermatitis (AD) Patients Induces Nonatopic Neonatal Thymic Gamma-Delta T Cells (gammadeltaT) to Acquire IL-22\/IL-17 Secretion Profile with Skin-Homing Properties and Epigenetic Implications Mediated by miRNA. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23126872"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/imcb.12335","article-title":"Do different IgG repertoires play a role in B- and T-cell functional modulation during ontogeny? The \u201chooks without bait\u201d theory","volume":"98","author":"Victor","year":"2020","journal-title":"Immunol. Cell Biol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1600-065X.2009.00766.x","article-title":"The significance of OX40 and OX40L to T-cell biology and immune disease","volume":"229","author":"Croft","year":"2009","journal-title":"Immunol. Rev."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1615\/CritRevImmunol.v29.i3.10","article-title":"The role of OX40-mediated co-stimulation in T-cell activation and survival","volume":"29","author":"Redmond","year":"2009","journal-title":"Crit. Rev. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0065-2776(10)05003-0","article-title":"OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology","volume":"105","author":"Ishii","year":"2010","journal-title":"Adv. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/cmi.2018.8","article-title":"Critical role of OX40 signaling in the TCR-independent phase of human and murine thymic Treg generation","volume":"16","author":"Kumar","year":"2019","journal-title":"Cell Mol. Immunol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.4049\/jimmunol.0901112","article-title":"Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right","volume":"183","author":"Ruby","year":"2009","journal-title":"J. Immunol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"eaan3085","DOI":"10.1126\/scitranslmed.aan3085","article-title":"Combined OX40L and mTOR blockade controls effector T cell activation while preserving T(reg) reconstitution after transplant","volume":"9","author":"Tkachev","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0140-6736(22)02037-2","article-title":"An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: A multicentre, double-blind, placebo-controlled phase 2b study","volume":"401","author":"Simpson","year":"2023","journal-title":"Lancet"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1517\/14656566.2.11.1903","article-title":"Sirolimus: A comprehensive review","volume":"2","author":"Kahan","year":"2001","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/164_2021_553","article-title":"Mechanistic Target of Rapamycin (mTOR) Inhibitors","volume":"272","author":"Wang","year":"2022","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Strauss, L., Czystowska, M., Szajnik, M., Mandapathil, M., and Whiteside, T.L. (2009). Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0005994"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/S0140-6736(18)30485-9","article-title":"Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: A single-arm, open-label, phase 1\/2 trial","volume":"391","author":"Lai","year":"2018","journal-title":"Lancet"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/exd.12463","article-title":"Topical application of rapamycin ointment ameliorates Dermatophagoides farina body extract-induced atopic dermatitis in NC\/Nga mice","volume":"23","author":"Yang","year":"2014","journal-title":"Exp. Dermatol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3904\/kjim.2021.363","article-title":"Metformin and its therapeutic applications in autoimmune inflammatory rheumatic disease","volume":"37","author":"Kim","year":"2022","journal-title":"Korean J. Intern. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"973986","DOI":"10.1155\/2014\/973986","article-title":"Metformin attenuates experimental autoimmune arthritis through reciprocal regulation of Th17\/Treg balance and osteoclastogenesis","volume":"2014","author":"Son","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"117854","DOI":"10.1016\/j.lfs.2020.117854","article-title":"The impact of metformin and aspirin on T-cell mediated inflammation: A systematic review of in vitro and in vivo findings","volume":"255","author":"Nyambuya","year":"2020","journal-title":"Life Sci."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"107575","DOI":"10.1016\/j.intimp.2021.107575","article-title":"The AMPK modulator metformin as adjunct to methotrexate in patients with rheumatoid arthritis: A proof-of-concept, randomized, double-blind, placebo-controlled trial","volume":"95","author":"Abdallah","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1166\/nnl.2017.2402","article-title":"Metformin Attenuates Atopic Dermatitis by Inhibiting CD40 Expression in CD11c+DC via the mTOR Pathway","volume":"9","author":"Pei","year":"2017","journal-title":"Nanosci. Nanotechnol. Lett."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.biotechadv.2018.09.005","article-title":"Butyric acid: Applications and recent advances in its bioproduction","volume":"36","author":"Jiang","year":"2018","journal-title":"Biotechnol. Adv."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"McNabney, S.M., and Henagan, T.M. (2017). Short Chain Fatty Acids in the Colon and Peripheral Tissues: A Focus on Butyrate, Colon Cancer, Obesity and Insulin Resistance. Nutrients, 9.","DOI":"10.3390\/nu9121348"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/19490976.2015.1134082","article-title":"Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism","volume":"7","author":"Morrison","year":"2016","journal-title":"Gut Microbes"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/jn\/134.2.479","article-title":"Microbial degradation products influence colon cancer risk: The butyrate controversy","volume":"134","author":"Lupton","year":"2004","journal-title":"J. Nutr."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.3390\/nu7042839","article-title":"Dietary gut microbial metabolites, short-chain fatty acids, and host metabolic regulation","volume":"7","author":"Kasubuchi","year":"2015","journal-title":"Nutrients"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3389\/fimmu.2015.00061","article-title":"The environment of regulatory T cell biology: Cytokines, metabolites, and the microbiome","volume":"6","author":"Hoeppli","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0016-5085(92)91094-K","article-title":"Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis","volume":"103","author":"Scheppach","year":"1992","journal-title":"Gastroenterology"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1089\/jmf.2017.4116","article-title":"Anti-Inflammatory Effects of a Mixture of Lactic Acid Bacteria and Sodium Butyrate in Atopic Dermatitis Murine Model","volume":"21","author":"Kim","year":"2018","journal-title":"J. Med. Food"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/all.14478","article-title":"Immune modulation via T regulatory cell enhancement: Disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases\u2014An EAACI position paper of the Task Force on Immunopharmacology (TIPCO)","volume":"76","author":"Adcock","year":"2021","journal-title":"Allergy"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"981126","DOI":"10.3389\/falgy.2022.981126","article-title":"Roles of type 1 regulatory T (Tr1) cells in allergen-specific immunotherapy","volume":"3","author":"Matsuda","year":"2022","journal-title":"Front. Allergy"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"912529","DOI":"10.3389\/fimmu.2022.912529","article-title":"Current Strategies to Modulate Regulatory T Cell Activity in Allergic Inflammation","volume":"13","author":"Bellinghausen","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clim.2014.03.016","article-title":"Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets\u2014Results of one year follow-up","volume":"153","author":"Mysliwiec","year":"2014","journal-title":"Clin. Immunol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(20)30167-7","article-title":"Regulatory cell therapy in kidney transplantation (The ONE Study): A harmonised design and analysis of seven non-randomised, single-arm, phase 1\/2A trials","volume":"395","author":"Sawitzki","year":"2020","journal-title":"Lancet"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"m3734","DOI":"10.1136\/bmj.m3734","article-title":"Regulatory T cells for minimising immune suppression in kidney transplantation: Phase I\/IIa clinical trial","volume":"371","author":"Roemhild","year":"2020","journal-title":"BMJ"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"717594","DOI":"10.3389\/fimmu.2021.717594","article-title":"Antigen Specific Regulatory T Cells in Kidney Transplantation and Other Tolerance Settings","volume":"12","author":"Hu","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_141","first-page":"3031","article-title":"Interim Results of a Phase 1 Trial of Treg Adoptive Cell Transfer (TRACT) in Living Donor Kidney Transplant Recipients","volume":"15","author":"Leventhal","year":"2015","journal-title":"Am. J. Transpl."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12967-017-1133-8","article-title":"Generation of donor-specific Tr1 cells to be used after kidney transplantation and definition of the timing of their in vivo infusion in the presence of immunosuppression","volume":"15","author":"Mfarrej","year":"2017","journal-title":"J. Transl. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1097\/TP.0000000000003149","article-title":"A Clinical Trial With Adoptive Transfer of Ex Vivo-induced, Donor-specific Immune-regulatory Cells in Kidney Transplantation-A Second Report","volume":"104","author":"Koyama","year":"2020","journal-title":"Transplantation"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"102822","DOI":"10.1016\/j.copbio.2022.102822","article-title":"Manufacturing next-generation regulatory T-cell therapies","volume":"78","author":"MacDonald","year":"2022","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1182\/blood.2021010784","article-title":"Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity","volume":"137","author":"Foster","year":"2021","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3389\/fonc.2018.00453","article-title":"CART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors","volume":"8","author":"Filley","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_147","first-page":"93","article-title":"Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives","volume":"65","author":"Gauthier","year":"2017","journal-title":"Curr. Res. Transl. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrclinonc.2017.156","article-title":"Tisagenlecleucel\u2014The first approved CAR-T-cell therapy: Implications for payers and policy makers","volume":"15","author":"Prasad","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"571","DOI":"10.4161\/mabs.21338","article-title":"CD19 as an attractive target for antibody-based therapy","volume":"4","author":"Hammer","year":"2012","journal-title":"MAbs"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"djv439","DOI":"10.1093\/jnci\/djv439","article-title":"Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy","volume":"108","author":"Dai","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.2147\/DDDT.S138765","article-title":"CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia","volume":"12","author":"Vairy","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.clml.2019.08.002","article-title":"SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents","volume":"19","author":"Madduri","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clim.2019.07.009","article-title":"Engineered ovalbumin-expressing regulatory T cells protect against anaphylaxis in ovalbumin-sensitized mice","volume":"207","author":"Abdeladhim","year":"2019","journal-title":"Clin. Immunol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jaci.2010.10.023","article-title":"Bet v 1-specific T-cell receptor\/forkhead box protein 3 transgenic T cells suppress Bet v 1-specific T-cell effector function in an activation-dependent manner","volume":"127","author":"Schmetterer","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1073\/pnas.0900408106","article-title":"Identification of IL-17-producing FOXP3+ regulatory T cells in humans","volume":"106","author":"Voo","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.4049\/jimmunol.1003099","article-title":"Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes","volume":"186","author":"McClymont","year":"2011","journal-title":"J. Immunol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1038\/s41467-018-07254-2","article-title":"Inflammation-induced Id2 promotes plasticity in regulatory T cells","volume":"9","author":"Hwang","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/eji.200838904","article-title":"Loss of FOXP3 expression in natural human CD4+ CD25+ regulatory T cells upon repetitive in vitro stimulation","volume":"39","author":"Hoffmann","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"7059","DOI":"10.1038\/s41598-018-25384-x","article-title":"Pathological conversion of regulatory T cells is associated with loss of allotolerance","volume":"8","author":"Hua","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/08923973.2018.1437625","article-title":"CRISPR and personalized Treg therapy: New insights into the treatment of rheumatoid arthritis","volume":"40","author":"Safari","year":"2018","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"a015552","DOI":"10.1101\/cshperspect.a015552","article-title":"Regulatory T-cell therapy in transplantation: Moving to the clinic","volume":"3","author":"Tang","year":"2013","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"20876","DOI":"10.1038\/s41598-020-77947-6","article-title":"High dose vitamin D(3) empowers effects of subcutaneous immunotherapy in a grass pollen-driven mouse model of asthma","volume":"10","author":"Hesse","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2500\/aap.2016.37.3921","article-title":"The clinical effect of vitamin D supplementation combined with grass-specific sublingual immunotherapy in children with allergic rhinitis","volume":"37","author":"Jerzynska","year":"2016","journal-title":"Allergy Asthma Proc."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"336","DOI":"10.4168\/aair.2023.15.3.336","article-title":"Randomized, Double-Blind, Placebo-Controlled Trial of Vitamin D Supplementation in the Build-up Phase of House Dust Mite-Specific Immunotherapy","volume":"15","author":"Chiewchalermsri","year":"2023","journal-title":"Allergy Asthma Immunol. Res."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/0190-9622(93)70033-P","article-title":"A novel therapy for atopic dermatitis with allergen-antibody complexes: A double-blind, placebo-controlled study","volume":"28","author":"Leroy","year":"1993","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/8\/1674\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:23:55Z","timestamp":1760127835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/8\/1674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":170,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["life13081674"],"URL":"https:\/\/doi.org\/10.3390\/life13081674","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,1]]}}}